The MYC proto-oncogenes encode a family of transcription factors that are among the most
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …

Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …

The transcription factor and oncoprotein MYC is a potent driver of many human cancers and
can regulate numerous biological activities that contribute to tumorigenesis. How a single …

The MYC gene which consists of 3 paralogs, C-MYC, N-MYC and L-MYC, is one of the most
frequently deregulated driver genes in human cancer. Because of its high prevalence of …

The loss of vital cells within healthy tissues contributes to the development, progression and
treatment outcomes of many human disorders, including neurological and infectious …

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co …

MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Nanotechnology offers new solutions for the development of cancer therapeutics that display
improved efficacy and safety. Although several nanotherapeutics have received clinical …

The term'undruggable'was coined to describe proteins that could not be targeted
pharmacologically. However, progress is being made to'drug'many of these targets, and …

The genetic concept of synthetic lethality has now been validated clinically through the
demonstrated efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of …